Fargnoli (Sidemast), ‘new psoriasis drug can improve patient’s quality of life’

“Psoriasis has a very impactful impact. It is necessary that today a patient can and must have treatment to get their life back. Drugs that lower the inflammatory burden also help reduce the risks of associated comorbidities. This new molecule (deucravacitinib) can help patients get their life back, because they often avoid social relationships because of psoriasis”. This was stated by Maria Concetta Fargnoli, professor of Dermatology at the University of L’Aquila (UnivAq) and vice president of Sidemast (Italian Society of Dermatology and Sexually Transmitted Diseases) during the press conference organized by Bristol Myers Squibb to announce the green light from Aifa to the reimbursement of deucravacitinib for the treatment of moderate to severe psoriasis.